OPHTALMIC COMPOSITION FOR TREATMENT OF OCULAR HYPERTENSION COMPRISING COMBINATION OF A CARBONIC ANHYDRASE INHIBITOR AND A BETA-ADRENERGIC ANTAGONIST

摘要

Combinations 0.01 to 1.0 wt. % beta-adrenergic antagonist and topical carbonic anhydrase inhibitor in an amount of 0.05 to 5 wt. are particularly suitable for the treatment of ocular hypertension, especially in patients with insufficient response to treatment with beta-adrenergic antagonists.